On November 15, 2024, Endo, Inc. announced a definitive agreement with MC2 Therapeutics to bring Wynzora® Cream (calcipotriene and betamethasone dipropionate) to Canada through its subsidiary, Paladin Pharma Inc. Wynzora® Cream is a topical treatment designed to address plaque psoriasis, a chronic autoimmune condition affecting the skin.

Livio Di Francesco, Vice President and General Manager of Paladin, expressed optimism about the partnership, stating, "We are excited to collaborate with MC2 Therapeutics to make Wynzora® Cream accessible to Canadians suffering from plaque psoriasis. If approved by Health Canada, this innovative treatment will offer a unique combination of efficacy and convenience, integrating seamlessly into patients' daily routines."

Jesper J. Lange, CEO of MC2 Therapeutics, shared similar enthusiasm for the collaboration. "We are delighted to partner with Paladin, whose experienced team is well-equipped to bring Wynzora® Cream to the Canadian market," Lange remarked. "This agreement reflects our commitment to expanding global access to Wynzora® Cream, ensuring that patients with plaque psoriasis have a new, effective treatment option."

Wynzora® Cream has already established a strong presence in international markets. It received FDA approval in the United States on July 20, 2020, and was subsequently launched in Europe on February 18, 2022. The cream’s unique PAD™ Technology delivers a combination of calcipotriene, a synthetic vitamin D3 analog, and betamethasone dipropionate, a corticosteroid, in a formulation optimized for ease of use and patient adherence.

The introduction of Wynzora® Cream to Canada aims to address a significant unmet need for plaque psoriasis patients, offering them a novel treatment that balances efficacy with convenience. Both companies anticipate a positive response from Health Canada and look forward to making this treatment widely available upon approval. This collaboration underscores Endo’s and MC2 Therapeutics’ shared commitment to improving the quality of life for individuals living with challenging dermatological conditions.

By leveraging Paladin’s expertise in the Canadian pharmaceutical market and MC2 Therapeutics’ innovative dermatological solutions, the partnership seeks to enhance the standard of care for plaque psoriasis patients in Canada. The move aligns with MC2’s broader global strategy to ensure that Wynzora® Cream becomes an accessible and trusted option for patients worldwide.

Wynzora® Cream is a topical treatment for plaque psoriasis, including scalp psoriasis, in adults. It combines calcipotriene and betamethasone dipropionate in a single cream-based formulation. The product's dual action targets key cytokines in the immune system—IL-23 and IL-17A/F—along with TNF-α expression, addressing the core drivers of the condition. Powered by MC2’s innovative PAD Technology™, Wynzora® Cream features a convenient, water-based formulation designed for easy use.